Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
Status:
Suspended
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept
study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially
controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with
long-acting beta 2 agonist (LABA).